ATE521624T1 - Peptide und medizinische zusammensetzungen mit denselben - Google Patents
Peptide und medizinische zusammensetzungen mit denselbenInfo
- Publication number
- ATE521624T1 ATE521624T1 AT03775859T AT03775859T ATE521624T1 AT E521624 T1 ATE521624 T1 AT E521624T1 AT 03775859 T AT03775859 T AT 03775859T AT 03775859 T AT03775859 T AT 03775859T AT E521624 T1 ATE521624 T1 AT E521624T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- pacap
- same
- provides
- medicinal compositions
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 2
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 2
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001373 regressive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000003419 tautomerization reaction Methods 0.000 abstract 1
- 239000002538 vasoactive intestinal polypeptide derivative Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002344523 | 2002-11-27 | ||
| PCT/JP2003/014924 WO2004048401A1 (ja) | 2002-11-27 | 2003-11-21 | ペプチド及びこれを含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521624T1 true ATE521624T1 (de) | 2011-09-15 |
Family
ID=32375955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03775859T ATE521624T1 (de) | 2002-11-27 | 2003-11-21 | Peptide und medizinische zusammensetzungen mit denselben |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7332473B2 (de) |
| EP (1) | EP1571155B1 (de) |
| JP (1) | JP4477506B2 (de) |
| KR (1) | KR20050067439A (de) |
| CN (1) | CN100381462C (de) |
| AT (1) | ATE521624T1 (de) |
| AU (1) | AU2003284428B2 (de) |
| CA (1) | CA2507616A1 (de) |
| ES (1) | ES2368565T3 (de) |
| WO (1) | WO2004048401A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005102375A1 (ja) * | 2004-04-23 | 2008-03-06 | 千寿製薬株式会社 | Ｐａｃａｐおよびその誘導体を含有する角膜神経突起形成促進剤 |
| CA2601279A1 (en) * | 2005-03-07 | 2006-09-14 | Mondobiotech Licensing Out Ag | Formulation for aviptadil |
| KR20080082597A (ko) * | 2005-07-28 | 2008-09-11 | 글로벌 리서치 테크놀로지스, 엘엘씨 | 공기로부터 이산화탄소의 제거 |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| EP2017289A4 (de) | 2006-04-20 | 2011-07-27 | Itoham Foods Inc | Pharmazeutische zusammensetzung für konformationskrankheit |
| AU2008297927A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of Trp6-Triptorelin and D-Leu6-Leuprolide as therapeutic agents |
| EP3412300A1 (de) | 2008-06-27 | 2018-12-12 | Duke University | Therapeutika mit elastinähnlichen peptiden |
| BRPI0914504B8 (pt) | 2008-10-17 | 2021-05-25 | Vectus Biosystems Pty Ltd | uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv |
| WO2011020091A1 (en) | 2009-08-14 | 2011-02-17 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
| EP2717902B1 (de) | 2011-06-06 | 2018-01-24 | Phasebio Pharmaceuticals, Inc. | Verwendung modifizierter vasoaktiver darmpeptide bei der behandlung von bluthochdruck |
| US11052132B2 (en) | 2014-05-08 | 2021-07-06 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
| CA2976038A1 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62246595A (ja) * | 1986-04-17 | 1987-10-27 | Eisai Co Ltd | 気菅支拡張作用・降圧作用ペプタイド |
| US4939224A (en) * | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
| SE8705139D0 (sv) * | 1987-12-23 | 1987-12-23 | Trion Forskning & Utveckling | Forfarande for framstellning av ett stort antal peptidanaloger och nya peptidanaloger |
| US5141924A (en) * | 1989-06-30 | 1992-08-25 | Hoffmann-La Roche, Inc. | Synthetic vasoactive intestinal peptide analogs |
| JPH0692991A (ja) * | 1991-02-28 | 1994-04-05 | Daicel Chem Ind Ltd | 新規活性ペプチド |
| US5623050A (en) * | 1991-08-22 | 1997-04-22 | Takeda Chemical Industries, Ltd. | Stable polypeptides having c-AMP production enhancing activity and the use thereof |
| JPH06220090A (ja) * | 1993-01-22 | 1994-08-09 | Sanwa Kagaku Kenkyusho Co Ltd | ポリペプチド |
| US5856303A (en) * | 1995-06-09 | 1999-01-05 | Itoham Foods, Inc. | Peptide, a bronchus-expanding agent, and a blood-flow-improving agent |
| JPH11100399A (ja) * | 1997-09-26 | 1999-04-13 | Itoham Foods Inc | 新規ペプチド誘導体およびそれを有効成分とする薬剤 |
| US6242563B1 (en) * | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
| JP2001226284A (ja) * | 2000-02-18 | 2001-08-21 | Itoham Foods Inc | 神経突起誘発剤 |
| JP2003073301A (ja) * | 2001-06-22 | 2003-03-12 | Itoham Foods Inc | 神経毒性低下剤 |
| WO2003039577A1 (en) * | 2001-11-06 | 2003-05-15 | Senju Pharmaceutical Co., Ltd. | Remedies for dry eye and diseases associated with dry eye |
| NZ533627A (en) * | 2001-12-19 | 2006-03-31 | Itoham Foods Inc | Remedies and/or preventatives for neurodegenerative diseases using VIP or PACAP peptides |
-
2003
- 2003-11-21 EP EP03775859A patent/EP1571155B1/de not_active Expired - Lifetime
- 2003-11-21 JP JP2004555011A patent/JP4477506B2/ja not_active Expired - Lifetime
- 2003-11-21 CN CNB2003801077640A patent/CN100381462C/zh not_active Expired - Fee Related
- 2003-11-21 US US10/536,880 patent/US7332473B2/en not_active Expired - Fee Related
- 2003-11-21 KR KR1020057009606A patent/KR20050067439A/ko not_active Abandoned
- 2003-11-21 AT AT03775859T patent/ATE521624T1/de not_active IP Right Cessation
- 2003-11-21 WO PCT/JP2003/014924 patent/WO2004048401A1/ja not_active Ceased
- 2003-11-21 CA CA002507616A patent/CA2507616A1/en not_active Abandoned
- 2003-11-21 ES ES03775859T patent/ES2368565T3/es not_active Expired - Lifetime
- 2003-11-21 AU AU2003284428A patent/AU2003284428B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP4477506B2 (ja) | 2010-06-09 |
| US7332473B2 (en) | 2008-02-19 |
| AU2003284428A1 (en) | 2004-06-18 |
| US20060276384A1 (en) | 2006-12-07 |
| EP1571155A4 (de) | 2005-12-28 |
| EP1571155B1 (de) | 2011-08-24 |
| CN100381462C (zh) | 2008-04-16 |
| EP1571155A1 (de) | 2005-09-07 |
| KR20050067439A (ko) | 2005-07-01 |
| CA2507616A1 (en) | 2004-06-10 |
| JPWO2004048401A1 (ja) | 2006-03-23 |
| WO2004048401A1 (ja) | 2004-06-10 |
| AU2003284428B2 (en) | 2010-08-26 |
| ES2368565T3 (es) | 2011-11-18 |
| CN1732182A (zh) | 2006-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE521624T1 (de) | Peptide und medizinische zusammensetzungen mit denselben | |
| ATE330595T1 (de) | Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie | |
| IL187438A0 (en) | Pyrrolopyridine derivatives and pharmaceutical compositions containing the same | |
| NO20042298L (no) | Farmasoytiske preparater og deres anvendelser | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| GEP201706611B (en) | Amido compounds and their use as pharmaceuticals | |
| ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| DE60228857D1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| DE602004014145D1 (de) | Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen | |
| ATE549353T1 (de) | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| BRPI0513051A (pt) | combinação de inibidores de transcriptase reversa e de protease anti-hiv | |
| ATE353231T1 (de) | Pharmazeutische zusammensetzungen | |
| DE602005027231D1 (de) | Cylglycerolen und therapeutischen verwendungen derselben | |
| TW200638927A (en) | Bambuterol and integrin inhibitor combination | |
| DE60036199D1 (de) | Proteaseresistente flint-analoge | |
| BR0011845A (pt) | Complexo farmacêutico | |
| SE0203817D0 (sv) | New composition | |
| DE602005023437D1 (de) | Als inhibitor von retroviraler protease geeignete ritonavir-analoge verbindung, herstellung der ritonavir-analogen verbindung und pharmazeutische zusammenetzung für die ritonavir-analoge verbindung | |
| EP1730174A4 (de) | Peptidträger für die verabreichung von arzneimitteln | |
| DE602004017062D1 (de) | Zusammensetzungen aus deramciclan und opioiden zur verwendung als schmerzmittel | |
| BR0215498A (pt) | Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |